جستجوی استاد راهنمای دانشگاهی

JIANG Xingyu is Chair Professor and Head of the Department of Biomedical Engineering at the Southern University of Science and Technology (SUSTech) . Since 2018 he has led a multidisciplinary team developing advanced micro- and nano-scale tools for analytical chemistry, microfluidics and nanomedicine. Education Postdoctoral Research, Harvard University (2004–2005) Ph.D. in Chemistry, Harvard University (2004) B.S. in Chemistry, University of Chicago (1999) Research Interests Professor Jiang’s research integrates analytical chemistry , microfluidics , biomedical engineering and nanomedicine . His laboratory designs microfluidic chips for point-of-care diagnostics, engineers gold nanoclusters and nanoparticles for antimicrobial and anticancer therapy, and develops soft flexible bio-electronics for neural interfaces and wearable health monitoring. Across 400+ publications, recent work demonstrates a clear trend toward translational nanomedicine : point-of-care viral variant detection, nanoantibiotic strategies against multidrug-resistant bacteria, CRISPR delivery systems for cancer therapy, and conformal electronic tattoos for human-machine interfaces. Scientific Awards & Honours Fellow, American Institute for Medical and Biological Engineering (2020) Fellow, Royal Society of Chemistry (2016) Tencent Science Exploration Award (2019) Chief Scientist, National Key R&D Program (2019–) National Science Fund for Distinguished Young Scholars (2010) Young Investigator Award, Human Frontier Science Program (2007) Research Funding & Teams He currently directs the Nanoscience Laboratory at SUSTech, hosts National Key R&D Program projects as Chief Scientist, and serves on editorial boards of Advanced Healthcare Materials , Lab on a Chip , Nanoscale Horizons , Nanoscale and Nanoscale Advances . The group is actively recruiting post-docs, research professors and technicians across chemistry, materials, biology and medical engineering disciplines.

• Analytical Chemistry
• Microfluidics
• Biomedical Engineering
• +۲ مورد دیگر

Shutao Ma is a Professor and Doctoral Supervisor at Shandong University's School of Pharmaceutical Sciences, serving as Director of the Department of Medicinal Chemistry since 2009. He has received the Special Government Allowance from China's State Council since 2002 and the seventh youth award of Shandong province for his contributions to medicinal chemistry. His academic credentials include: Ph.D. in Pharmaceutical Sciences, Shandong University (2004-2007) M.Sc. in Pharmaceutical Sciences, Shandong Medical University (1988-1991) B.Sc. in Pharmaceutical Sciences, Shandong Medical University (1981-1986) Professor Ma's research pioneers innovative strategies against antibiotic-resistant bacteria through three interconnected pillars: 1) Designing FtsZ/AcrB-targeted small molecules to disrupt bacterial cell division and efflux mechanisms; 2) Structural optimization of macrolides, glycopeptides, and lipopeptides to overcome resistance; 3) Total synthesis and mechanistic studies of marine-derived antibacterial natural products. His work bridges synthetic chemistry with microbiological validation to develop next-generation antimicrobials. Analysis of his 15 most recent publications (2014-2016) reveals a dominant focus on antibacterial drug discovery (87% of works), particularly FtsZ inhibitors (33%) and macrolide derivatives (27%). Emerging themes include quorum sensing modulation (7%) and antiviral/anticancer applications (13%), demonstrating strategic expansion while maintaining core expertise in resistance mechanisms. His scientific recognition includes: First prize of Shandong science and technology progress award (2000) Special government allowance from the State Council (2002) The seventh youth awards of Shandong province (2002) As a Doctoral Supervisor, Professor Ma mentors the next generation of medicinal chemists while directing a robust research program funded by 12 major grants. His National Natural Science Foundation portfolio (2004-2020) spans antibacterial discovery, while Shandong Provincial grants (2006-2017) and China-Australia collaborations (2014-2017) support translational development of resistance-breaking agents. Leading the Department of Medicinal Chemistry, he oversees a multidisciplinary team integrating synthetic chemistry, microbiology, and computational modeling to advance antibacterial drug candidates from concept to preclinical validation, with particular emphasis on FtsZ-targeted therapeutics and macrolide engineering.

• Medicinal Chemistry
• Antibacterial Drug Discovery
• Antibiotic Resistance
• +۳ مورد دیگر

CHEN Wei is a Chair Professor at the Department of Biology, School of Life Sciences, Southern University of Science and Technology (SUSTech), Shenzhen, China. He holds a Ph.D. from the Max Planck Institute for Molecular Genetics (2006) and previously served as a Full Professor (W3) at the Max-Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin (2015-2016). Prior to joining SUSTech, he led research groups at prestigious German institutions, contributing to large-scale genome centers and the Berlin Institute of Health. Education : Ph.D. (2006, Max Planck Institute), M.S. (2002, Sichuan University), B.S. (1993, Xiamen University) His research focuses on systems biology and genomics, particularly post-transcriptional gene regulation mechanisms and their roles in human diseases. His lab integrates next-generation sequencing technologies with computational approaches to study non-coding RNA functions, alternative splicing, and chromatin dynamics. Key projects include CRISPR-based functional studies, 3D genome analysis, and RNA editing in neurological and metabolic disorders. Recent publications highlight his work in Drosophila developmental genomics, chloroplast translation control, and cancer biology. The 2025 study on spatiotemporal multi-omics in Drosophila and 2024 articles on MatK's role in tRNA splicing and CRISPR-activated transcriptional regulation exemplify his interdisciplinary approach. Earlier works (2023-2022) address immune cell trafficking, alternative polyadenylation, and chromatin remodeling in cancer metastasis. At SUSTech, he leads a team with 4 research assistant professors, 2 postdoctoral fellows, 3 research assistants, and 7 graduate students. His lab has secured significant funding from EU and German agencies (€7M+), though specific awards are not detailed in the provided text. Teaching responsibilities include General Biology and Principles of Cell Biology.

• Systems Biology
• Genomics
• Post-transcriptional Gene Regulation
• +۳ مورد دیگر

Liu Hongmei is a Researcher and Master's Supervisor at Southern University of Science and Technology's Department of Biomedical Engineering. Holding a Ph.D. from the Chinese Academy of Sciences, she specializes in micro-nano robotics and tissue engineering for tumor therapy, with over 66 publications and 12 patents. Her work bridges biomedical engineering and nanotechnology for precision cancer treatments. B.S., Biological Sciences, Harbin Normal University (2005) M.S., Botany, Northeast Agricultural University (2008) Ph.D., Biochemical Engineering, Chinese Academy of Sciences (2015) Her research focuses on biomaterials engineering , nanoparticle drug delivery , and microenvironment-responsive hydrogels . Key areas include glioma therapy, traumatic brain injury recovery, and intervertebral disc degeneration treatments. Recent work explores pH/ROS/inflammation-triggered hydrogels and bioengineered bacteria for disease modulation. Article trends show a strong emphasis on nanoparticle design (2014-2025) for glioma, hydrogel development (2017-2025) for tissue repair, and biomimetic material synthesis (2023-2025) inspired by spider silk and meniscus structures. Sub-fields span pyroptosis inhibition, epigenetic reprogramming, and microbiome engineering. Jiangsu Science and Technology Award (2020) Jiangsu Medical Science and Technology Award (2020) Jiangsu Educational Science Research Award (2021) Chinese Medical Doctor Association's Outstanding Young Scientist (2018) Liu has supervised numerous projects including National Natural Science Foundation of China grants, Jiangsu Province Key R&D Program funding, and Shenzhen City General Projects. She holds 12 Chinese invention patents and collaborates with institutions like the UNESCO Centre for Higher Education Innovation.

• Biomedical Engineering
• Nanotechnology
• Tumor Therapy
• +۴ مورد دیگر

Prof. Huayu Tian is a Nan Qiang Distinguished Professor at the Department of Chemistry, College of Chemistry and Chemical Engineering, Xiamen University. With a Ph.D. in Polymer Chemistry and Physics from Changchun Institute of Applied Chemistry (CAS), he leads research in biomedical polymers and nanocarriers for gene/drug delivery. B.S. (1994-1998): Polymer Materials, Harbin Institute of Technology M.S. (1998-2000): Materials Science, Harbin Institute of Technology Ph.D. (2002-2005): Polymer Chemistry, Changchun Institute His work focuses on biomedical polymers , nanocarriers for gene therapy , nucleic acid vaccines , and immunotherapy , with applications in cancer treatment and sepsis management . Recent publications highlight photothermal-immunotherapy combinations , MOF-based drug systems , and microenvironment-responsive nanomaterials . Notable awards include: Jilin Province Natural Science Award (First Prize, 2021) National Outstanding Youth Fund (China) Youth Innovation Promotion Association, CAS (2016)

• Biomedical polymers
• Nano-gene/drug carriers
• Biotherapy
• +۳ مورد دیگر

Huanhuan CUI is a Research Associate Professor in the Department of Biology within the School of Life Sciences at Southern University of Science and Technology (SUSTech) in Shenzhen, China. She joined SUSTech in December 2018 and serves as a master's supervisor, contributing to both research and graduate education in molecular biology and genetics. Educational Background: PhD in Biology, Free University of Berlin (2011.09-2016.04) MS in Animal Genetics, Northwest A&F University (2008.09-2010.06) BE in Bioengineering, Northwest A&F University (2004.09-2008.06) Dr. CUI's research focuses on the mechanisms and method development of gene transcription and epigenetic regulation, with particular emphasis on RNA translation control. Her work spans multiple biological systems including cancer biology, developmental biology, and cardiovascular research, demonstrating a strong interdisciplinary approach that integrates molecular biology, genomics, and bioinformatics techniques. She has made significant contributions to understanding chromatin remodeling, transcriptional regulation, and RNA processing mechanisms. Dr. CUI's publication record shows a consistent trajectory of high-impact research, with publications in prestigious journals including Nature Communications, Nucleic Acids Research, and Cellular & Molecular Immunology. Her work demonstrates expertise in CRISPR-based technologies, epigenetic regulation, and multi-omics approaches to studying complex biological processes. Before joining SUSTech, Dr. CUI held positions as a Clinical Research Manager at BGI Genomics (2017.09-2018.11), a PostDoc at Charite Universitaetsmedizin Berlin (2016.05-2017.06), and a Research Assistant at Humboldt University of Berlin (2010.09-2011.08), building a diverse research background that bridges basic science and clinical applications.

• Gene Transcription
• Epigenetic Regulation
• RNA Regulation
• +۱ مورد دیگر

Dr. Jianyang HU serves as a Research Assistant Professor in the Department of Biochemistry at the School of Medicine, Southern University of Science and Technology (SUSTech). He joined SUSTech in July 2021 after completing postdoctoral training at City University of Hong Kong, where he earned his PhD in Biomedical Sciences in 2020. His educational background includes a Master's in Pharmacology from Jinan University (2012-2015) and a Bachelor's in Pharmacy from Guangzhou University of Chinese Medicine (2008-2012). His research focuses on tumor cell senescence regulation , cancer metastasis mechanisms , and cell-cell communications in the tumor microenvironment , particularly through exosome-mediated pathways. His work primarily investigates triple-negative breast cancer using models like circulating tumor cells. Dr. HU's publication record shows strong engagement in cancer biology with 13 papers in high-impact journals including Nature Communications (IF:17.694) and British Journal of Cancer (IF:9.08), accumulating over 480 citations and an H-index of 10. His research spans molecular oncology, drug discovery, and cancer pharmacology with emphasis on transcriptional regulation, stemness, and metastasis. National Natural Science Foundation Youth Project Shenzhen Science and Technology Innovation Commission Youth Project China Postdoctoral Program Guangdong Overseas Postdoctoral Talents Support Project He has applied for 3 Chinese patents and 2 US patents related to cancer therapeutics. Currently working in Prof. Xin Hong's research group at SUSTech, Dr. HU's work aims to identify novel drug targets for tumor treatment through mechanistic studies of cellular senescence and metastasis.

• Tumor Cell Senescence
• Cancer Metastasis
• Tumor Microenvironment
• +۳ مورد دیگر

Yuhui Hu is an Associate Professor and Doctoral Supervisor in the Department of Pharmacology, School of Medicine at Southern University of Science and Technology (SUSTech) in Shenzhen, China. She joined SUSTech in August 2016 as an independent PI and was promoted to Associate Professor in the Department of Pharmacology in March 2022, having previously served as a Research Associate Professor in the Department of Biology, School of Life Sciences at SUSTech from 2016-2022. Dr. Hu earned her Ph.D. in Functional Genomics from the Max Planck Institute for Molecular Genetics in Berlin, Germany in 2006. Prior to joining SUSTech, she led her own research group on pharmacogenomics and chemical genetics at the same institute from 2007-2009, then moved to the Berlin Institute for Medical Systems Biology (BIMSB) at the Max Delbrück Center for Molecular Medicine where she served as a Senior Research Scientist until 2016. Her research focuses on integrating diverse systems biology approaches in transcriptomics, genomics/epigenomics, proteomics, CRISPR gene editing, single-cell and spatiotemporal omics to decipher gene regulations in cancer precision medicine and developmental biology. She has pioneered high-throughput platforms for protein subcellular localization, apoptosis detection, and protein-protein interaction analysis. Her work bridges traditional Chinese medicine compounds with modern systems biology approaches to develop new drugs, particularly through the investigation of natural compounds for anticancer and anti-COVID applications. Her recent publications show a strong focus on cutting-edge single-cell and spatial transcriptomics technologies, with multiple high-impact papers in journals like Cell, Nature Communications, and Developmental Cell. Her research group has developed several innovative protocols for sample multiplexing and cell death quantification compatible with single-cell sequencing. Excellent Patent Award, Southern University of Science and Technology (2020) Industrial Development and Innovative Talent Award, Shenzhen (2021) Shenzhen Peacock Talent Award As a Doctoral Supervisor, Dr. Hu leads a research group that has secured significant funding, including six national/provincial projects totaling over ¥7.14 million. She serves as a core PI in the Shenzhen Key Laboratory of Gene Regulation and Systems Biology and holds several academic society positions, including committee member of the division of anti-inflammatory and immunological pharmacology of the Chinese Pharmacological Society, council member of Guangdong Pharmacological Society, and executive director of Guangdong Overseas Returnees Association. Her lab continues to develop novel systems biology approaches for gene regulation and pharmacology research, with a particular focus on cancer genomics and chemical genomics for early diagnosis, therapy, and prognosis.

• Functional Genomics
• Systems Biology
• Pharmacogenomics
• +۱۱ مورد دیگر

Dan HUANG is an Assistant Professor in the Department of Basic Immunology and Microbiology at the School of Life Sciences, Southern University of Science and Technology. He obtained his Ph.D. in Chemical Pathology from The Chinese University of Hong Kong (2014-2018) and a Bachelor's degree in Bioinformatics from Harbin Medical University (2008-2013). His professional journey includes postdoctoral research at SUSTech (2021-2023) and The Chinese University of Hong Kong (2019-2020), plus a Chief Scientist role at Cytomics Limited (2020-2021). Research Interests: Genomic Evolution Tumor Metabolism Transcriptional Regulatory Mechanisms Publication Trends (2020-2023): His work focuses on leveraging multi-omics data to uncover mechanisms in cancer resistance, including RNA methylation (m6A), microbiome interactions, and evolutionary adaptations of tumor suppressor genes. Key themes include immunotherapy optimization, epigenetic regulation, and cross-disciplinary applications of bioinformatics to clinical and environmental contexts. Academic Background: Ph.D., Chemical Pathology, The Chinese University of Hong Kong (2014-2018) Bachelor's, Bioinformatics, Harbin Medical University (2008-2013)

• Genomic Evolution
• Tumor Metabolism
• Transcriptional Regulatory Mechanisms
• +۳ مورد دیگر

Hu Chengzhi is a tenured Associate Professor at the Department of Mechanical and Energy Engineering , Southern University of Science and Technology (SUSTech), where he has worked since 2018. He leads the SUSTech-Zifu Medical Joint Laboratory (5 million RMB funding) and serves as Deputy Director of the Guangdong Provincial Key Laboratory of Human Augmentation and Rehabilitation Robots . A National Young Talent Program recipient and Shenzhen Peacock Plan B-category Talent , he earned his PhD in Micro-Nano Systems Engineering from Nagoya University (2014) under Professor Toshio Fukuda (Chinese Academy of Sciences foreign member) and conducted postdoctoral work at ETH Zurich with Professor Bradley Nelson. Education B.S. & M.S. in Mechanical Engineering, Huazhong University of Science and Technology (2008, 2010) Ph.D. in Micro-Nano Systems Engineering, Nagoya University (2014) Research Interests focus on micro-nano robotic technologies for single-cell analysis and tumor-targeted therapy , including magnetic manipulation, microfluidic chips, and swimming microrobots. His work also extends to medical microrobotics for diagnosing and treating gastrointestinal diseases. Over the past five years, he has led 14 competitive projects, including the National Key R&D Program and National Natural Science Foundation of China grants. Scientific Awards include the 2024 MINE Young Scientist Award , Best Paper Awards at IEEE MHS 2012, IEEE ICRA 2015, IEEE CBS 2023, and IEEE ICMA 2024. He has published 65 papers in top journals like Nature Communications , Advanced Science , and ACS Nano , and holds over 30 patents. Leadership and Service : Served as General Chair for IEEE ICMA 2025 (500+ participants), Director of SUSTech-Zifu Medical Joint Laboratory , and editorial board member of Cyborg and Bionic Systems . He mentors PhD and Master's students and actively recruits researchers for his lab.

• Micro-Nano Robotics
• Single-Cell Analysis
• Tumor-Targeted Therapy
• +۴ مورد دیگر

Deng Yi is a Teaching Professor in the Department of Biology at Southern University of Science and Technology (SUSTech), where she has established herself as a leading researcher in cell-matrix adhesion mechanisms and their implications for disease. She joined SUSTech in 2012 as an Associate Professor and was promoted to Teaching Professor in 2020, following extensive postdoctoral training at the National Institutes of Health (NIH) in the United States. Educational Background: PhD in Biology from Ruhr-University Bochum (Germany), 2002 MS in Biology from Shandong University, 1999 BS in Biology from Shandong University, 1996 Research Interests: Dr. Deng's research program focuses on understanding the molecular mechanisms of cell-extracellular matrix interactions and their relationship to health and disease. Her laboratory investigates how cell-matrix adhesions regulate cell motility, growth, and signaling pathways through the formation of key protein complexes including ILK-PINCH-parvin and kindlin-migfilin-filamin. Using advanced fluorescence microscopy techniques combined with biochemical approaches, her team studies these dynamic processes at multiple spatial scales. Her work has significant implications for understanding cancer metastasis, tumor development, and pancreatic beta-cell function in diabetes. Publication Trends: Analysis of Dr. Deng's recent publications reveals a strong focus on integrin-mediated cell adhesion mechanisms, with increasing attention to cancer biology applications in her most recent work. Her research spans developmental biology using Xenopus models, structural biology of adhesion proteins, and translational studies in diabetes and cancer. The consistent use of advanced imaging techniques and molecular approaches demonstrates methodological coherence across her publication portfolio. Scientific Recognition: Extensive publication record in high-impact journals including PNAS, Journal of Biological Chemistry, and Oncogene Research contributions to understanding kindlin-mediated integrin activation mechanisms Significant findings on RSU1 regulation of MEK-ERK signaling in tumor development Teaching and Mentoring: Dr. Deng is actively involved in undergraduate education at SUSTech, teaching core courses including Molecular Biology (BIO320), Cell Biology (BIO206), and Advanced Cell Biology (BIO323). She emphasizes hands-on research experience for students and integrates her cutting-edge research findings into classroom instruction. Her laboratory provides research opportunities for undergraduate and graduate students interested in cell biology and disease mechanisms. Research Infrastructure: Dr. Deng leads a well-equipped research team within the Department of Biology at SUSTech, utilizing advanced cell biology techniques including live-cell imaging and fluorescence-based technologies. Her laboratory collaborates with other research groups at SUSTech and maintains connections with international collaborators, particularly in Germany and Hong Kong where she conducted earlier research.

• Cell-Matrix Adhesion
• Signal Transduction
• Cancer Metastasis
• +۳ مورد دیگر

Dong Jintang is a Chair Professor and Head of the Department of Human Cell Biology and Genetics at the Southern University of Science and Technology (SUSTech) School of Medicine. He earned a BS in Biology from Nankai University (1984) and a PhD in Pathophysiology from Peking Union Medical College and the Chinese Academy of Medical Sciences (1989). His postdoctoral training at NIH and Johns Hopkins focused on molecular cancer biology and prostate cancer. He held academic positions at the University of Virginia (1996-2001), Emory University (2002-2018), and Nankai University (2006-2018 as Adjunct Professor). Since 2018, he has led SUSTech's School of Medicine research team. His research centers on molecular pathogenesis of human cancers, particularly prostate cancer progression. Using genetic, biochemical, and molecular approaches, he investigates oncogenes like KAI1, PTEN, and transcription factors (KLF5, ATBF1) in tumor development, metastasis, and therapeutic resistance. He has contributed to epigenetic mechanisms in breast cancer and identified novel tumor suppressors such as snoRNA U50. His publications (over 120 peer-reviewed articles, including in Science , Nature Genetics , and Nature Communications ) reveal frequent themes in prostate cancer mutations, KLF5/WWP1 oncogenic interactions, and hormone-dependent tumor regulation. Recent work explores SUMOylation of ZFHX3 in liver cancer and KLF5's dual role in epithelial homeostasis versus oncogenesis. Scientific awards include the Georgia Cancer Alliance's Outstanding Doctor and Scientist Award, Yangtze River Scholar Specially Appointed Professor status, and National Thousand Talents Plan recognition. He has trained over 30 doctoral students and postdocs, served on editorial boards of journals like Journal of Genetics and Genomics , and led NIH-funded projects. His lab at SUSTech investigates molecular targets for cancer diagnostics and therapeutics.

• Molecular Cancer Biology
• Prostate Cancer
• Oncogenes
• +۳ مورد دیگر

Dr. Ziwei Dai is an Assistant Professor at the Department of Biology, Southern University of Science and Technology, where she leads interdisciplinary research bridging computational and systems biology. She completed her PhD in Physical Chemistry at Peking University's Center for Quantitative Biology in 2016 and conducted postdoctoral training at Duke University's Department of Pharmacology and Cancer Biology (2016-2020). Research Focus: Cancer metabolism (glucose & amino acid dysregulation) Metabolic regulation of epigenetics/gene expression Biological network modeling Multi-omics data analysis Publication Trends: Her 15 most recent works (2018-2021) demonstrate expertise in metabolic network modeling, cancer epigenetics, and computational approaches to nutrient metabolism. Common subfields include flux analysis, chromatin biology, and tumor microenvironment characterization. Scientific Recognition: Robert J. Fitzgerald Scholar Award (2018) National Graduate Scholarship (2014) President Scholarship, Peking University (2014) Her research has achieved over 1,200 citations by 2021 and includes multiple cover articles in journals like Nature , Cell Metabolism , and Science Advances .

• Cancer Metabolism
• Epigenetic Regulation
• Systems Biology
• +۳ مورد دیگر

Yuliang Feng is an Associate Professor and doctoral supervisor in the Department of Pharmacology, School of Medicine, Southern University of Science and Technology (SUSTech), China. He also serves as Vice-Chair of the Pan-Vascular Committee of the Guangdong Medical Education Association and holds editorial/reviewer roles for more than 25 international journals. Education Ph.D. in Molecular & Cellular Medicine, University of Oxford, UK (2019-2022) M.D. in Cardiovascular Pharmacology, Joint Ph.D. program, Southern Medical University & University of Cincinnati (2008-2014) B.M. in Preventive Medicine, Sun Yat-sen University, China (2003-2008) Research Interests Dr. Feng integrates 3-D genomics , epigenomics and computational biology to decode how higher-order chromatin organization governs transcriptional programs in human disease, with a focus on cardiovascular disease and cancer . His laboratory maps enhancer–promoter interactions using Hi-C, ChIA-PET and HiChIP, and develops multi-omics databases (e.g., EXPRESSO) to uncover therapeutic targets that reprogram pathological gene networks. Recent work reveals shared genetic architectures among major cardiovascular diseases, telomere-length contributions to disease onset, BRD9–SMAD2/3-mediated stemness in pancreatic cancer, and 3-D chromatin rewiring during dilated cardiomyopathy. These studies highlight his expertise in translating genome topology findings into diagnostic and precision-medicine strategies. Scientific Awards & Honors National Science Foundation of China Distinguished Young Scholar (Overseas), 2023 Guangdong Distinguished Young Scholar, 2023 Shenzhen Pengcheng Peacock Talent (Category C), 2023 Clarendon Scholar, University of Oxford, 2019-2022 ISHR Richard J. Bing Young Investigator Award Finalist, 2022 Multiple ISHR Young Investigator & Travel Awards (2010-2016) Grants & Leadership Dr. Feng currently leads projects funded by the National Natural Science Foundation of China and Guangdong Province, and participates in international consortia such as ENCODE, 4DN and BLUEPRINT. He mentors graduate students and postdocs, while coordinating collaborative teams across SUSTech, Oxford, and industry partners to develop next-generation epigenomic therapeutics. Laboratory & Teams The Feng lab operates within the SUSTech Medical Research Platform with access to state-of-the-art sequencing, single-cell and high-performance computing cores. The group maintains active collaborations with cardiac surgeons, oncologists and AI scientists to accelerate bench-to-bedside translation of 3-D genome-based interventions.

• 3-D genomics
• epigenomics
• chromatin topology
• +۵ مورد دیگر

Xun Li is an Associate Professor in the Department of Medicinal Chemistry at the School of Pharmaceutical Science, Shandong University. She has been affiliated with the institution since 2004, holding roles as Lecturer, Postdoctoral Fellow, and Associate Professor. Education: Ph.D. in Chemistry from Shandong University and Tianjin University (2004), B.S. in Chemistry from Qufu Normal University (1999). Professional Experience: 2004-2006 Lecturer & Postdoctoral Fellow; 2006-present Associate Professor; Visiting Scholar at Tokyo University (2007, 2008). Her research focuses on anti-tumor agents , peptidomimetics , multidrug resistance (MDR) reversal , matrix metalloproteinase (MMP) inhibitors , and aminopeptidase N (APN) inhibitors . She has published extensively on quinoxalinone derivatives and their roles in cancer therapy. Scientific Awards include: Excellent Postdoctoral Research Fellowship of China (2005) Youth Research Fellowship of 40th IUPAC (2005) Second-Class Shandong Province Science and Technology Progress Award (2012) She has secured multiple grants , including National Natural Foundation Research Grants and Japan-China Collaborative Research Grants, and holds several patents for quinoxalinone derivatives with MDR reversal and MMP inhibition activity.

• Anti-tumor agents
• Peptidomimetics
• Multidrug resistance (MDR)
• +۴ مورد دیگر